6 results on '"Reginato S"'
Search Results
2. VEGF dose regulates vascular stabilization through Semaphorin3A and the Neuropilin-1+ monocyte/TGF- 1 paracrine axis
- Author
-
Groppa E., Brkic S., Bovo E., Reginato S., Sacchi V., Di Maggio N., Muraro M. G., Calabrese D., Heberer M., Gianni-Barrera R., and Banfi A.
- Abstract
VEGF is widely investigated for therapeutic angiogenesis but while short term delivery is desirable for safety it is insufficient for new vessel persistence jeopardizing efficacy. Here we investigated whether and how VEGF dose regulates nascent vessel stabilization to identify novel therapeutic targets. Monoclonal populations of transduced myoblasts were used to homogeneously express specific VEGF doses in SCID mouse muscles. VEGF was abrogated after 10 and 17 days by Aflibercept treatment. Vascular stabilization was fastest with low VEGF but delayed or prevented by higher doses without affecting pericyte coverage. Rather VEGF dose dependently inhibited endothelial Semaphorin3A expression thereby impairing recruitment of Neuropilin 1 expressing monocytes (NEM) and decreasing TGF ß1 and endothelial SMAD2/3 activation. TGF ß1 further initiated a feedback loop stimulating endothelial Semaphorin3A expression thereby amplifying the stabilizing signals. Blocking experiments showed that NEM recruitment required endogenous Semaphorin3A and that TGF ß1 was necessary to start the Semaphorin3A/NEM axis. Conversely Semaphorin3A treatment promoted NEM recruitment and vessel stabilization despite high VEGF doses or transient adenoviral delivery. Therefore VEGF inhibits the endothelial Semaphorin3A/NEM/TGF ß1 paracrine axis and Semaphorin3A treatment accelerates stabilization of VEGF induced angiogenesis.
- Published
- 2015
- Full Text
- View/download PDF
3. EphrinB2/EphB4 signaling regulates non-sprouting angiogenesis by VEGF.
- Author
-
Groppa E, Brkic S, Uccelli A, Wirth G, Korpisalo-Pirinen P, Filippova M, Dasen B, Sacchi V, Muraro MG, Trani M, Reginato S, Gianni-Barrera R, Ylä-Herttuala S, and Banfi A
- Subjects
- Animals, Cells, Cultured, Endothelial Cells metabolism, Female, Humans, Intussusception, Ischemia pathology, Mice, Mice, Inbred C57BL, Mice, Knockout, Mice, SCID, Muscle, Skeletal pathology, Neovascularization, Pathologic pathology, Phosphorylation, Vascular Endothelial Growth Factor Receptor-2 metabolism, Ephrin-B2 metabolism, Myoblasts metabolism, Neovascularization, Pathologic metabolism, Receptor, EphB4 metabolism, Signal Transduction, Vascular Endothelial Growth Factor A metabolism
- Abstract
Vascular endothelial growth factor (VEGF) is the master regulator of angiogenesis, whose best-understood mechanism is sprouting. However, therapeutic VEGF delivery to ischemic muscle induces angiogenesis by the alternative process of intussusception, or vascular splitting, whose molecular regulation is essentially unknown. Here, we identify ephrinB2/EphB4 signaling as a key regulator of intussusceptive angiogenesis and its outcome under therapeutically relevant conditions. EphB4 signaling fine-tunes the degree of endothelial proliferation induced by specific VEGF doses during the initial stage of circumferential enlargement of vessels, thereby limiting their size and subsequently enabling successful splitting into normal capillary networks. Mechanistically, EphB4 neither inhibits VEGF-R2 activation by VEGF nor its internalization, but it modulates VEGF-R2 downstream signaling through phospho-ERK1/2. In vivo inhibitor experiments show that ERK1/2 activity is required for EphB4 regulation of VEGF-induced intussusceptive angiogenesis. Lastly, after clinically relevant VEGF gene delivery with adenoviral vectors, pharmacological stimulation of EphB4 normalizes dysfunctional vascular growth in both normoxic and ischemic muscle. These results identify EphB4 as a druggable target to modulate the outcome of VEGF gene delivery and support further investigation of its therapeutic potential., (© 2018 The Authors. Published under the terms of the CC BY NC ND 4.0 license.)
- Published
- 2018
- Full Text
- View/download PDF
4. Therapeutic angiogenesis due to balanced single-vector delivery of VEGF and PDGF-BB.
- Author
-
Banfi A, von Degenfeld G, Gianni-Barrera R, Reginato S, Merchant MJ, McDonald DM, and Blau HM
- Subjects
- Adenoviridae genetics, Animals, Becaplermin, Gene Transfer Techniques, Genetic Therapy methods, Genetic Vectors, HEK293 Cells, Hindlimb blood supply, Humans, Male, Mice, Mice, SCID, Muscle, Skeletal blood supply, Platelet-Derived Growth Factor therapeutic use, Proto-Oncogene Proteins c-sis administration & dosage, Vascular Endothelial Growth Factor A administration & dosage, Neovascularization, Physiologic physiology, Proto-Oncogene Proteins c-sis therapeutic use, Vascular Endothelial Growth Factor A therapeutic use
- Abstract
Therapeutic angiogenesis by delivery of vascular growth factors is an attractive strategy for treating debilitating occlusive vascular diseases, yet clinical trials have thus far failed to show efficacy. As a result, limb amputation remains a common outcome for muscle ischemia due to severe atherosclerotic disease, with an overall incidence of 100 per million people in the United States per year. A challenge has been that the angiogenic master regulator vascular endothelial growth factor (VEGF) induces dysfunctional vessels, if expressed outside of a narrow dosage window. We tested the hypothesis that codelivery of platelet-derived growth factor-BB (PDGF-BB), which recruits pericytes, could induce normal angiogenesis in skeletal muscle irrespective of VEGF levels. Coexpression of VEGF and PDGF-BB encoded by separate vectors in different cells or in the same cells only partially corrected aberrant angiogenesis. In marked contrast, coexpression of both factors in every cell at a fixed relative level via a single bicistronic vector led to robust, uniformly normal angiogenesis, even when VEGF expression was high and heterogeneous. Notably, in an ischemic hindlimb model, single-vector expression led to efficient growth of collateral arteries, revascularization, increased blood flow, and reduced tissue damage. Furthermore, these results were confirmed in a clinically applicable gene therapy approach by adenoviral-mediated delivery of the bicistronic vector. We conclude that coordinated expression of VEGF and PDGF-BB via a single vector constitutes a novel strategy for harnessing the potency of VEGF to induce safe and efficacious angiogenesis.
- Published
- 2012
- Full Text
- View/download PDF
5. To sprout or to split? VEGF, Notch and vascular morphogenesis.
- Author
-
Gianni-Barrera R, Trani M, Reginato S, and Banfi A
- Subjects
- Animals, Cellular Microenvironment, Humans, Neovascularization, Physiologic, Blood Vessels growth & development, Morphogenesis, Receptors, Notch metabolism, Vascular Endothelial Growth Factor A metabolism
- Abstract
Therapeutic angiogenesis is an attractive strategy to treat patients suffering from peripheral or coronary artery disease. VEGF (vascular endothelial growth factor-A) is the fundamental factor controlling vascular growth in both development and postnatal life. The interplay between the VEGF and Notch signalling pathway has been recently found to regulate the morphogenic events leading to the growth of new vessels by sprouting. Angiogenesis can also take place by an alternative process, i.e. intussusception or vascular splitting. However, little is known about its role in therapeutic angiogenesis and its molecular regulation. In the present article, we briefly review how VEGF dose determines the induction of normal or aberrant angiogenesis and the molecular regulation of sprouting angiogenesis by Notch signalling, and compare this process with intussusception.
- Published
- 2011
- Full Text
- View/download PDF
6. Taming of the wild vessel: promoting vessel stabilization for safe therapeutic angiogenesis.
- Author
-
Reginato S, Gianni-Barrera R, and Banfi A
- Subjects
- Animals, Endothelium, Vascular cytology, Endothelium, Vascular metabolism, Humans, Pericytes cytology, Pericytes metabolism, Vascular Endothelial Growth Factor A genetics, Vascular Endothelial Growth Factor A therapeutic use, Blood Vessels growth & development, Genetic Therapy, Neovascularization, Physiologic
- Abstract
VEGF (vascular endothelial growth factor) is the master regulator of blood vessel growth. However, it displayed substantial limitations when delivered as a single gene to restore blood flow in ischaemic conditions. Indeed, uncontrolled VEGF expression can easily induce aberrant vascular structures, and short-term expression leads to unstable vessels. Targeting the second stage of the angiogenic process, i.e. vascular maturation, is an attractive strategy to induce stable and functional vessels for therapeutic angiogenesis. The present review discusses the limitations of VEGF-based gene therapy, briefly summarizes the current knowledge of the molecular and cellular regulation of vascular maturation, and describes recent pre-clinical evidence on how the maturation stage could be targeted to achieve therapeutic angiogenesis.
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.